Clinical Trials
586
Active:45
Completed:329
Trial Phases
6 Phases
Early Phase 1:8
Phase 1:25
Phase 2:25
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (431 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
331 (76.8%)Phase 4
37 (8.6%)Phase 1
25 (5.8%)Phase 2
25 (5.8%)Early Phase 1
8 (1.9%)Phase 3
5 (1.2%)Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Active, not recruiting
- Conditions
- Cardiovascular Kidney Metabolic Syndrome
- Interventions
- Drug: InterventionDrug: Active Comparator
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 23280000
- Registration Number
- NCT07188545
- Locations
- πΊπΈ
Ohio State University, Columbus, Ohio, United States
SPIRIT Club Chronic Brain Injury Exercise Platform
Not Applicable
Not yet recruiting
- Conditions
- Chronic Brain Injury
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 60
- Registration Number
- NCT07169370
- Locations
- πΊπΈ
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Nutrition Supplement for Cystic Fibrosis
Not Applicable
Not yet recruiting
- Conditions
- Cystic Fibrosis (CF)
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 60
- Registration Number
- NCT07163078
Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity
Not Applicable
Not yet recruiting
- Conditions
- Adequate Vitamin C StatusInadequate Vitamin C Status
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 34
- Registration Number
- NCT07151105
Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.
Not Applicable
Recruiting
- Conditions
- Oral LeukoplakiaOral Dysplasia
- Interventions
- Drug: Mucoadhesive fenretinide-releasing system (FMS)
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 25
- Registration Number
- NCT07149220
- Locations
- πΊπΈ
Ohio State University College of Dentistry, Columbus, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 118
- Next
News
Neucore Bio Receives $350K NIH Grant to Develop Exosome-Based Gene Therapy for Charcot-Marie-Tooth Disease
Neucore Bio secured a $350,000 STTR Phase I grant from NIH's NCATS to develop an exosome-based RNA therapy targeting Charcot-Marie-Tooth Disease Type 1A.